Unknown

Dataset Information

0

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.


ABSTRACT: Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin's lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, even though the benefits of this approach remain uncertain. This study retrospectively examined outcomes in a cohort of North American PTCL patients treated with both anthracycline- and nonanthracycline-containing regimens. The incorporation of anthracycline-containing regimens was associated with improved progression-free survival (PFS) and overall survival (OS). Patients treated with nonanthracycline-containing regimens were more likely to have high-risk features and were less likely to undergo high-dose therapy and stem cell transplantation. However, anthracycline use remained an independent predictor of improved PFS and OS when adjusting for these confounding variables. Anthracycline-based regimens and consolidation with high-dose therapy and autologous stem cell transplantation in appropriately selected patients remains a viable option for patients unable to participate in a clinical trial. Long-term disease-free survival is not optimal, highlighting the need for an improved understanding of disease pathogenesis, and the development of novel therapeutic strategies.

SUBMITTER: Briski R 

PROVIDER: S-EPMC4042304 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.

Briski R R   Feldman A L AL   Bailey N G NG   Lim M S MS   Ristow K K   Habermann T M TM   Macon W R WR   Inwards D J DJ   Colgan J P JP   Nowakowski G S GS   Kaminski M S MS   Witzig T E TE   Ansell S M SM   Wilcox R A RA  

Blood cancer journal 20140530


Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin's lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, even though the benefits of this approach remain uncertain. This study retrospectively examined outcomes in a cohort of North American PTCL patients treated with both anthracycline- and nonanthracycline-conta  ...[more]

Similar Datasets

| S-EPMC3197255 | biostudies-other
| S-EPMC9818471 | biostudies-literature
| S-EPMC4376730 | biostudies-literature
| S-EPMC4171358 | biostudies-literature
| S-EPMC7887017 | biostudies-literature
| S-EPMC2394229 | biostudies-other
| S-EPMC6995391 | biostudies-literature
| S-EPMC4746094 | biostudies-literature
| S-EPMC10485051 | biostudies-literature
| S-EPMC7362384 | biostudies-literature